Multiple Myeloma
Conditions
Interventions
Arm A: Mezigdomide, Carfilzomib and Dexamethasone
Arm B: Carfilzomib and Dexamethasone
Sponsors
Engelhardt Brian
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participant has documented diagnosis of Multiple Myeloma and measurable disease. Participant has received at least 1 prior line of anti-myeloma therapy. Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody.
Exclusion criteria
Exclusion criteria: Participant who has had prior treatment with mezigdomide or carfilzomib. Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, Overall Response, Very good partial response, Complete response, Time to Response, Duration of Response, Time to Progression, Time to Next Treatment, Progression-free Survival 2, adverse events | — |
Countries
Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Denmark, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Netherlands, Norway, Singapore, Spain, Taiwan, UK, USA
Contacts
Public ContactBrian Engelhardt
Bristol-Myers Squibb
Outcome results
None listed